<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974190</url>
  </required_header>
  <id_info>
    <org_study_id>0037-21-COM1</org_study_id>
    <nct_id>NCT04974190</nct_id>
  </id_info>
  <brief_title>A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Grasses of Eden Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sherutei Briut Clalit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Grasses of Eden Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Nasal Spray device containing Dead Sea minerals and plant extracts, used to shorten&#xD;
      duration and mitigate effects of Covid-19 infection in mild to moderate adult patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Nasal Spray device containing Dead Sea minerals and plant extracts, designed to incur a&#xD;
      PPAR-alpha agonistic effect, used to shorten duration and mitigate effects of Covid-19&#xD;
      infection in mild to moderate adult patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A control group is allocated a placebo solution</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Covid-19 infection self-testing on days 2, 4 following testing positive on PCR test</measure>
    <time_frame>First 7 days after testing positive on PCR test</time_frame>
    <description>Testing using a self testing kit of the Quidel QuickView type</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms monitoring</measure>
    <time_frame>First 7 days after testing positive on PCR test</time_frame>
    <description>Monitoring any disease symptoms reported by patient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Patients treated with actual device with actual solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with actual device with placebo solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal Spray Device</intervention_name>
    <description>A Nasal Spray apparatus containing a liquid</description>
    <arm_group_label>Patients treated with actual device with actual solution</arm_group_label>
    <arm_group_label>Patients treated with actual device with placebo solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Having tested positive to Covid-19 on PCR test -&#xD;
&#xD;
        Exclusion Criteria: Pregnancy Low blood pressure On immune system suppressing medications&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

